Non-small Cell Lung Cancer Therapeutics Market Size, Share & Trends Report

Non-small Cell Lung Cancer Therapeutics Market Size, Share & Trends Analysis Report By Drug (Alimta, Iressa, Avastin, Tarceva, Zykadia, Tagrisso, Xalkori, Cyramza), By Region, & Segment Forecasts, 2018 - 2025

  • Report ID: GVR-1-68038-703-2
  • Number of Pages: 100
  • Format: Electronic (PDF)
  • Historical Range: 2014 - 2016
  • Industry: Healthcare

Market Segmentation

  • Non-small Cell Lung Cancer Therapeutics Drug Outlook (Revenue, USD Million, 2014 - 2025)
    • Alimta
    • Iressa
    • Avastin
    • Tarceva
    • Zykadia
    • Tagrisso
    • Xalkori
    • Cyramza
    • Opdivo
    • Alecensa
  • Non-small Cell Lung Cancer Therapeutics Regional Outlook (Revenue, USD Million, 2014 - 2025)
    • North America
      • The U.S.
        • U.S. Drug Outlook (Revenue, USD Million, 2014 - 2025)
          • Alimta
          • Iressa
          • Avastin
          • Tarceva
          • Zykadia
          • Tagrisso
          • Xalkori
          • Cyramza
          • Opdivo
          • Alecensa
      • Canada
        • Canada Drug Outlook (Revenue, USD Million, 2014 - 2025)
          • Alimta
          • Iressa
          • Avastin
          • Tarceva
          • Zykadia
          • Tagrisso
          • Xalkori
          • Cyramza
          • Opdivo
          • Alecensa
    • Europe
      • UK
        • UK Drug Outlook (Revenue, USD Million, 2014 - 2025)
          • Alimta
          • Iressa
          • Avastin
          • Tarceva
          • Zykadia
          • Tagrisso
          • Xalkori
          • Cyramza
          • Opdivo
          • Alecensa
      • Germany
        • Germany Drug Outlook (Revenue, USD Million, 2014 - 2025)
          • Alimta
          • Iressa
          • Avastin
          • Tarceva
          • Zykadia
          • Tagrisso
          • Xalkori
          • Cyramza
          • Opdivo
          • Alecensa
    • Asia Pacific
      • Japan
        • Japan Drug Outlook (Revenue, USD Million, 2014 - 2025)
          • Alimta
          • Iressa
          • Avastin
          • Tarceva
          • Zykadia
          • Tagrisso
          • Xalkori
          • Cyramza
          • Opdivo
          • Alecensa
      • China
        • China Drug Outlook (Revenue, USD Million, 2014 - 2025)
          • Alimta
          • Iressa
          • Avastin
          • Tarceva
          • Zykadia
          • Tagrisso
          • Xalkori
          • Cyramza
          • Opdivo
          • Alecensa
    • Latin America
      • Brazil
        • Brazil Drug Outlook (Revenue, USD Million, 2014 - 2025)
          • Alimta
          • Iressa
          • Avastin
          • Tarceva
          • Zykadia
          • Tagrisso
          • Xalkori
          • Cyramza
          • Opdivo
          • Alecensa
      • Mexico
        • Mexico Drug Outlook (Revenue, USD Million, 2014 - 2025)
          • Alimta
          • Iressa
          • Avastin
          • Tarceva
          • Zykadia
          • Tagrisso
          • Xalkori
          • Cyramza
          • Opdivo
          • Alecensa
    • MEA
      • South Africa
        • South Africa Drug Outlook (Revenue, USD Million, 2014 - 2025)
          • Alimta
          • Iressa
          • Avastin
          • Tarceva
          • Zykadia
          • Tagrisso
          • Xalkori
          • Cyramza
          • Opdivo
          • Alecensa

Report content

Qualitative Analysis

  • Industry overview
  • Industry trends
  • Market drivers and restraints
  • Market size
  • Growth prospects
  • Porter’s analysis
  • PESTEL analysis
  • Key market opportunities prioritized
  • Competitive landscape
    • Company overview
    • Financial performance
    • Product benchmarking
    • Latest strategic developments

Quantitative Analysis

  • Market size, estimates, and forecast from 2014 to 2025
  • Market estimates and forecast for product segments up to 2025
  • Regional market size and forecast for product segments up to 2025
  • Market estimates and forecast for application segments up to 2025
  • Regional market size and forecast for application segments up to 2025
  • Company financial performance
What questions do you have? Get quick response from our industry experts. Request a Free Consultation
pdf

GET A FREE SAMPLE

bck

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

cog

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

esomar icon

ESOMAR certified & member

ISO

ISO Certified

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.

great place to work icon